Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

New Target May Be Eyed in Kids' Brain Cancer

Scientists closer to understanding the development of deadly neuroectodermal tumors


Related Encyclopedia
 border=
Adenocarcinoma of the Lung and Brain Metastases
Attention Deficit/Hyperactivity Disorder
Basal Cell Carcinoma
Bladder Cancer
More...

Related Healthscout Videos
 border=
Growing Lungs in the Lab: Medicine's Next Big Thing?
From Belly to Breast: Rebuilding After Cancer
Shaving off Cancer
Fluorescent Medicine for Brain Tumors
More...

Related Animations
 border=
ADHD
Breast Self-Exam Video
Colon Cancer
More...

Related Drug Information
 border=
Epogen
Iressa
Procrit
Topamax
More...

Related News Articles
 border=
Poor Children Get Biggest Literacy Boost From Preschool
Long-Term Statin Use Won't Up Cancer Risk: Study
Smokers Urged to Join Thursday's Great American Smokeout
FDA Advisers Renew Review on Whether to Ban Menthol Cigarettes
More...

MONDAY, Dec. 7 (HealthDay News) -- Scientists have identified oncogenes that play a role in a particularly aggressive type of childhood brain tumor.

Known as central nervous system primitive neuroectodermal tumors (CNS-PNETs), the discovery of these oncogenes may lead to improved diagnosis and treatment of the deadly condition.

Text Continues Below



"Lack of insight into the molecular pathogenesis of CNS-PNET is a major obstacle towards development of disease-specific models and treatments for these frequently fatal malignancies," noted senior study author Dr. Annie Huang, of the Hospital for Sick Children in Toronto.

She and colleagues from Asia, Europe and the United States conducted a high resolution genomic screen of CNS-PNET tumors and found that a DNA segment that contains a group of 54 microRNA (miRNA) genes was present in many copies in aggressive tumor cells.

The specific miRNAs from this C19MC group can stimulate growth and prevent development of normal human neural stem cells into more mature types of brain cells, the researchers said. They also found that the C19MC miRNA oncogenes can cause aggressive tumors by altering signaling pathways that regulate normal neural stem cell growth.

"Our findings highlight C19MC as an attractive candidate biomarker and therapeutic target for aggressive pediatric brain tumors and support an emerging theme that miRNAs are important determinants of tumor biology," Huang said. "Together with recent reports which implicate C19MC miRNAs in aggressive primary breast cancer, our findings suggest activation of the C19MC locus may generally define aggressive human tumors."

The study appears in the December issue of Cancer Cell.

More information

The Nemours Foundation has more about childhood brain tumors.



-- Robert Preidt

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 12/7/2009

Related Links
 border=
From Healthscout's partner site on breast cancer, MyBreastCancerNetwork.com
VIDEO: Chemo booster cuts treatment time by two months
SYMPTOMS: Learn what to look for and what the symptoms mean
PROGNOSIS: Early detection and new treatments improve survival rates





SOURCE: Cell Press, news release, Dec. 7, 2009


HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2010. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire